HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HemoGenyx Pharmaceuticals has made significant strides in the first half of 2024, with the FDA lifting the clinical hold on their HEMO-CAR-T treatment for acute myeloid leukemia, leading to a successful £3.325 million fundraising to initiate Phase I trials at MD Anderson Cancer Center. The company also reported progress in their CBR and CDX programs and a lower half-year loss compared to the previous year, due to favorable currency exchange rates and reduced R&D costs. As HemoGenyx moves into clinical trials, they are well-positioned for growth and look forward to offering new therapies for serious blood diseases.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
